Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCTL | Q9NXS2 | 10/20 | 0.72 |
| ▸ | QPCT | Q16769 | 9/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8183779 | 1.00 | QPCTL (0.72) | QPCTLQPCTMEN1ALDH1A1LMNA | |
| SCHEMBL3630094 | 1.00 | QPCTL (0.72) | QPCTLQPCTMEN1ALDH1A1LMNA | |
| SCHEMBL5068647 | 0.87 | QPCTL (0.68) | QPCTLQPCT | |
| SCHEMBL8178664 | 0.87 | QPCTL (0.68) | QPCTLQPCT | |
| SCHEMBL3628537 | 0.87 | QPCTL (0.68) | QPCTLQPCT | |
| SCHEMBL8178668 | 0.86 | QPCTL (0.75) | QPCTLQPCT | |
| SCHEMBL5064357 | 0.84 | QPCTL (1.00) | QPCTLQPCT | |
| SCHEMBL8179674 | 0.84 | QPCTL (1.00) | QPCTLQPCT | |
| SCHEMBL3633782 | 0.84 | QPCTL (1.00) | QPCTLQPCT | |
| SCHEMBL3628261 | 0.82 | QPCTL (1.00) | QPCTLQPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772508-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2014-07-08 | — | — | US | claimed |
| EP-2142513-B1 | NITROVINYL-DIAMINE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2014-03-12 | — | — | EP | claimed |
| US-20080292582-A1 | imidazole derivatives; Alzheimer's Disease, Down syndrome and Huntington's Disease; hypotensive agents; sleeping and eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 1-(3,4-dimethoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea | PROBIODRUG AG (DE) | 2008-11-27 | — | — | US | claimed |
| US-8772508-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2014-07-08 | — | — | US | disclosed |
| EP-2142513-B1 | NITROVINYL-DIAMINE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-20080292582-A1 | imidazole derivatives; Alzheimer's Disease, Down syndrome and Huntington's Disease; hypotensive agents; sleeping and eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 1-(3,4-dimethoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea | PROBIODRUG AG (DE) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080292582-A1 | imidazole derivatives; Alzheimer's Disease, Down syndrome and Huntington's Disease; hypotensive agents; sleeping and eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 1-(3,4-dimethoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea | HTT, MAPT, HYPK | QPCTL 3689/4885QPCT 4555/4885MEN1 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.